InVivium Capital
Venture capitalChicago · Seed–Late Stage · 6 people tracked
Investment thesis
The firm believes healthcare is undergoing dramatic transformation and presents significant opportunity for innovation. It invests in groundbreaking technologies that can deliver meaningful and lasting change to health outcomes and the delivery of care. The firm partners directly with entrepreneurs and teams to bring these transformational technologies to market.
Source: firm website, verified Jul 21, 2026.
Team · 6 people
from the firm's websiteA venture capital investor with 25 years of experience and founder/managing partner of InVivium Capital focusing on life sciences investments. Previously spent 16 years as a partner at Baird Capital overseeing healthcare venture investments, with earlier experience as a healthcare investor at Advent Venture Partners and an operating role at Cortek in spinal orthopedics.
A partner at InVivium Capital with prior experience as a principal at Baird Capital leading healthcare investments. Earlier career included venture investing focused on medical devices and data analytics at Baxter Healthcare, roles at McKinsey & Company and Genentech, and strategy work at Healthbox.
A partner at InVivium Capital who is currently CEO of Lightswitch Capital, a private equity firm in biotechnology. He was previously vice chairman of BrightSphere, a NYSE-listed asset manager with over $240 billion in assets, and earlier worked as a corporate associate at Weil, Gotshal & Manges LLP.
Vice president of HR & operations at InVivium Capital with 11 years of prior experience at GCM Grosvenor, where she worked in both fund accounting and human resources.
An IP advisor with over 15 years of experience in intellectual property, healthcare reimbursement, and technology commercialization. She has worked on both entrepreneurial and venture capital sides, helping lead funding rounds and conducting investment due diligence on healthcare technology commercialization strategies.
An operating partner at InVivium Capital with investment experience across biotechnology, sustainability, carbon markets, and agriculture. Previously spent eight years as an operating partner at Pegasus Capital Advisors and has held roles at Diomics Corporation and Rose Capital.
What they invest in
from 1 of 13 portfolio companiesBiotech ×1Medical Devices ×1
HQs:United States×2
Investments · 13 tracked
founders shown can be your intro pathA biotechnology company developing precision medicine for the brain.
A biotechnology company developing targeted therapies for rare respiratory diseases.
Avalyn Pharma develops a nebulized inhalation treatment for pulmonary fibrosis designed to improve tolerability compared to existing oral therapies by directly delivering the drug to the lungs.
BiotechMedical Devices
Lyn Baranowski(CEO)
A biotechnology company developing a revolutionary class of therapeutics called Bionic Biologics.
A biotechnology company developing a ground-breaking platform of therapeutics called GEM-DIMERs.
A biotechnology company developing a pipeline of first-in-class, pan cancer therapies.
A biotechnology company developing a next generation, fully recombinant botulinum toxin.
Board seats · per SEC filings · 2
what is this? ⓘ$45M raise · filed Nov 2023 · via Michael Nixon Liang
$50M raise · filed Nov 2021 · via Amy Len Kobe
Inferred from directors named on each company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does InVivium Capital invest at?
- InVivium Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does InVivium Capital focus on?
- InVivium Capital focuses on Biotech, Healthtech, Medical Devices.
- Where is InVivium Capital located?
- InVivium Capital is headquartered in Chicago, US.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
USVP is a venture capital firm with over 40 years of history across four generations of technology investing. The firm has deployed $4.7B across 542 companies, generating 97 IPOs, and combines 150 years of combined operating experience with deep expertise in enterprise software, security, consumer technology, and healthcare.
A venture capital firm that supports founders developing transformative solutions across interconnected systems, with a particular focus on leveraging artificial intelligence and related technologies to advance health and human flourishing.